Objective To re-assess the Meta-analyses/network Meta-analyses on baloxavir marboxil in the treatment of influenza, and provide evidence-based reference for clinical use of baloxavir marboxil. Methods Meta-analyses/network Meta-analyses on baloxavir marboxil in the treatment of influenza were retrieved from PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP databases, with retrieval time from the inception of each database to December 11, 2023. Literatures were screened according to the inclusion and exclusion criteria. Information of included literatures was extracted, and the methodological quality, reporting quality and evidence quality of the included literatures were assessed by assessment of multiple systematic reviews 2 (AMSTAR-2) scale, preferred reporting items for systematic reviews and Meta-analyses (PRISMA) statement, as well as grading of recommendations, assessment, development, and evaluation (GRADE) system, respectively. Results A total of 7 Meta-analyses/network Meta-analyses were included. The results showed that in terms of alleviation time of influenza symptoms, the efficacy of baloxavir marboxil was not inferior to oseltamivir, peramivir, and zanamivir. In terms of the decrease in influenza virus titer 48 hours after medication, baloxavir marboxil was superior to oseltamivir and zanamivir. In terms of safety, baloxavir marboxil had a lower risk of drug-related adverse events than oseltamivir, and was comparable to peramivir and zanamivir. The overall assessment result of methodological quality of AMSTAR-2 scale was relatively low, with 2 literatures being classified as low-level and 5 as extremely low-level. PRISMA scores ranged 15.5-22. The quality of overall report was moderate. Two lite-ratures were scored >21, and the reports were relatively complete. There were 5 literatures with scores ranging 15-21, and the reports had certain deficiencies. The GRADE evidence quality grading results showed that among the included 199 outcome indicators, 4 indicators were high-level evidence, 49 were moderate-level evidence, 118 indicators were low-level evidence, and 28 indicators were extremely low-level evidence. Conclusion Baloxavir marboxil is comparable to neuraminidase inhibitors in the alleviation time of influenza symptoms, superior to oseltamivir and zanamisvir in decreasing virus titer, and has a lower risk of adverse drug events (especially nausea) than oseltamivir.